We are live on ! Find out more
FRA

Front Row Advisors Portfolio holdings

AUM $296M
1-Year Est. Return 34.73%
This Fund
S&P 500
This Quarter Est. Return
+17.22%
1 Year Est. Return
+34.73%
3 Year Est. Return
+122.22%
5 Year Est. Return
+164.22%
10 Year Est. Return
–
AUM
$270M
AUM Growth
+$52.1M
Cap. Flow
+$22M
Cap. Flow %
8.14%
Top 10 Hldgs %
40.76%
Holding
941
New
464
Increased
200
Reduced
32
Closed
8

Top Buys

Rank Stock Value
1
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$1.34M
2
XOM icon
ExxonMobil
XOM
+$1.31M
3
CVX icon
Chevron
CVX
+$1.25M
4
LLY icon
Eli Lilly
LLY
+$685K
5
JPM icon
JPMorgan Chase
JPM
+$684K

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$1.18M
2
NVDA icon
NVIDIA
NVDA
+$618K
3
AVGO icon
Broadcom
AVGO
+$138K
4
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$113K
5
AAPL icon
Apple
AAPL
+$105K

Sector Composition

Rank Sector Weight
1 Technology 44.15%
2 Healthcare 9.98%
3 Consumer Staples 7.57%
4 Financials 6.32%
5 Industrials 6.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RIOT icon
826
Riot Platforms
RIOT
$8.52B
$245 ﹤0.01%
20
– –
ADAM
827
Adamas Trust
ADAM
$777M
$215 ﹤0.01%
+29
New +$221
EGRX
828
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$210 ﹤0.01%
40
– –
RBLX icon
829
Roblox
RBLX
$34B
$191 ﹤0.01%
5
– –
PCG icon
830
PG&E
PCG
$47.8B
$184 ﹤0.01%
11
– –
QQQM icon
831
Invesco NASDAQ 100 ETF
QQQM
$95.1B
$183 ﹤0.01%
+1
New +$176
STHO icon
832
Star Holdings Shares of Beneficial Interest
STHO
$112M
$155 ﹤0.01%
+12
New +$150
VYX icon
833
NCR Voyix
VYX
$1.06B
$152 ﹤0.01%
12
– –
ARKG icon
834
ARK Genomic Revolution ETF
ARKG
$1.51B
$144 ﹤0.01%
+5
New +$150
RMAX icon
835
RE/MAX Holdings
RMAX
$200M
$132 ﹤0.01%
+15
New +$145
GAIA icon
836
Gaia
GAIA
$47.3M
$123 ﹤0.01%
40
– –
NATL icon
837
NCR Atleos
NATL
$3.52B
$119 ﹤0.01%
6
– –
KHC icon
838
Kraft Heinz
KHC
$30.4B
– –
-250
Closed -$9.08K
GTX icon
839
Garrett Motion
GTX
$5.9B
$99 ﹤0.01%
+10
New +$92
EHAB
840
DELISTED
Enhabit
EHAB
$82 ﹤0.01%
+7
New +$70
TVRD
841
Tvardi Therapeutics
TVRD
$23.5M
$73 ﹤0.01%
2
– –
CNDT icon
842
Conduent
CNDT
$230M
$68 ﹤0.01%
20
– –
AGEN
843
Agenus
AGEN
$249M
$58 ﹤0.01%
5
– –
CHRN
844
ChronoScale Holdings
CHRN
$3.12B
$42 ﹤0.01%
2
– –
RLMD icon
845
Relmada Therapeutics
RLMD
$544M
$28 ﹤0.01%
6
– –
FSR
846
DELISTED
Fisker Inc.
FSR
$21 ﹤0.01%
1,000
– –
CRDF icon
847
Cardiff Oncology
CRDF
$64.3M
$11 ﹤0.01%
2
– –
RAD
848
DELISTED
Rite Aid Corporation
RAD
$8 ﹤0.01%
50
– –
GTBP icon
849
GT Biopharma
GTBP
$11.7M
$4 ﹤0.01%
1
-1
-50% -$5
MBOT icon
850
Microbot Medical
MBOT
$115M
$1 ﹤0.01%
1
– –
31 32 33
34
35

Similar funds

SM
Skaana Management Brooklyn, New York $296M AUM 65.1% 1-Year Est. Return
RHP
Royal Harbor Partners Houston, Texas $295M AUM 14.06% 1-Year Est. Return
MSWM
Master's Wealth Management Lancaster, Pennsylvania $295M AUM 15.96% 1-Year Est. Return
RLIM
Red Lighthouse Investment Management New York $296M AUM 22.04% 1-Year Est. Return
JCM
Jacobsen Capital Management Salt Lake City, Utah $296M AUM 24.47% 1-Year Est. Return
CA
Claar Advisors New York $295M AUM 12.26% 1-Year Est. Return
NRC
New Republic Capital Charlotte, North Carolina $297M AUM 24.5% 1-Year Est. Return
MFC
Morris Financial Concepts Mount Pleasant, South Carolina $295M AUM 17.25% 1-Year Est. Return

Front Row Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Front Row Advisors held 941 positions worth $270M, up 24% from $218M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Front Row Advisors deployed $22M of net new capital in Q1 2024, opening 464 new positions and adding to 200 existing holdings. Its largest new stake was Vanguard Information Technology ETF: 8,008 shares worth $525K.

By sector, the portfolio is most concentrated in Technology at 44% of assets, down from 46% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Pfizer, an estimated $1.18M trimmed.

  • Front Row Advisors's largest Q1 2024 buy was Vanguard Information Technology ETF: 8,008 shares worth $525K.
  • Front Row Advisors added most to Berkshire Hathaway Class B in Q1 2024, an estimated $1.34M increase.
  • Front Row Advisors's biggest Q1 2024 reduction was Pfizer, cutting an estimated $1.18M.
  • Front Row Advisors fully exited Atlantica Sustainable Infrastructure plc Ordinary Shares in Q1 2024, selling an estimated $16.2K.
  • Front Row Advisors's ten largest holdings make up 41% of its $270M portfolio in Q1 2024.
  • Front Row Advisors opened 464 new positions and closed 8 in Q1 2024.
  • Front Row Advisors's portfolio value rose 24% quarter-over-quarter to $270M.

Based on Front Row Advisors's 13F filing for Q1 2024, filed 14 May 2024.